X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
Under the agreement, Clearmind will use the joint patent it has with BIRAD for innovative cocaine treatment using CMND-100 (5-methoxy-2-aminoindane), its novel psychedelic molecule.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 01, 2024
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
The combination treatment includes palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity, and depression.
Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: SCI-210
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2023
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area: Nutrition and Weight Loss Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
The Company will use the proceeds for clinical and pre-clinical testing of company's product candidates, including MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule which reduce the desire to consume alcoholic beverages.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aegis Capital Corp.
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 18, 2023
Details:
The Company will use the proceeds for clinical and pre-clinical testing of company's product candidates, including MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule which reduce the desire to consume alcoholic beverages.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aegis Capital Corp.
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 14, 2023
Details:
The agreement aims to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100, a novel psychedelic-derived drug candidate, to treat Alcohol Use Disorder.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johns Hopkins University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 06, 2023
Details:
The collaboration aims to evaluate Clearmind's and SciSparc's combination treatment of MEAI (5-methoxy-2-aminoindane), a novel proprietary psychedelic treatment, and PEA (phenethylamine), the active ingredient of CannAmide, for obesity and metabolic syndrome.
Lead Product(s): 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area: Nutrition and Weight Loss Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hebrew University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2023
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
CMND-100 is an once-a-day oral capsule, a MEAI (5-methoxy-2-aminoindane) based psychedelic-derived drug candidate which is being investigated for the treatment of alcohol use disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane,CannAmide
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2023
Details:
Under the agreement, IMP will be responsible for the global clinical supply chain of Clearmind’s proprietary drug candidate CMND-100 (5-methoxy-2-aminoindane) from manufacture to the various clinical sites.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: IMP Clinical Supply Services
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 02, 2023
Details:
The collaboration aims to strengthens IP portfolio with patent application in the U.S. For treatment of depression. The latest patent application refers to the protection of the unique combination of MEAI and SciSparc's Palmitoylethanolamide (PEA).
Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 21, 2023
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane,CannAmide
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Company expects to use the net proceeds, for general corporate purposes, which may include operating expenses, research and development of CMND-100 (5-methoxy-2-aminoindane), including clinical and pre-clinical testing of its product, working capital, future acquisition.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aegis Capital Corp.
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 06, 2023
Details:
The net proceeds will be used for the research and development of CMND-100 (5-methoxy-2-aminoindane), a novel psychoactive molecule that has been reported to reduce the desire to consume alcoholic beverages while exerting a euphoric alcohol-like experience.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aegis Capital Corp.
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 04, 2023
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane,CannAmide
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
Under the collaboration, three provisional patent applications were filed by Clearmind. The patent applications refer to novel proprietary combinations of LSD, psilocybin, and DMT and SciSparc’s Palmitoylethanolamide, the active ingredient of its proprietary CannAmide™.
Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 15, 2023
Details:
CMND-100 (5-methoxy-2-aminoindane), which is Clearmind’s lead compound, is a novel psychedelic-derived drug candidate, exhibiting compelling evidence that suggests a significant reduction of desire to consume alcoholic beverages- addressing a global unmet need.
Lead Product(s): 5-Methoxy-2-Aminoindane,CannAmide
Therapeutic Area: Nutrition and Weight Loss Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane,CannAmide
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane,CannAmide
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
The animals treated with MEAI (5-methoxy-2-aminoindane) showed increased energy expenditure, better fat utilization and weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation and well-being was observed.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
CMND-100, which is Clearmind’s lead compound, is a novel psychedelic-derived drug candidate, exhibiting compelling evidence that suggests a significant reduction of desire to consume alcoholic beverages- addressing a global unmet need.
Lead Product(s): 5-Methoxy-2-Aminoindane,CannAmide
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
The produced batches will be used in the Company's upcoming first in human (FIH) clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2022
Details:
MEAI (5-methoxy-2-aminoindane) is a novel psychoactive aminoindane derivative, exerting euphoric, alcohol-like tipsy experience and reduced desire to consume alcoholic beverages.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aegis Capital Corp.
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 17, 2022
Details:
The patent application is the third collaboration, each referring to the combination of SciSparc's Palmitoylethanolamide (PEA), the active ingredient of CannAmide™ and Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions.
Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 22, 2022
Details:
The dedicated treatment indicated significant decrease in cocaine craving in sub- group that received Clearmind's MEAI (5-methoxy-2-aminoindane) its novel psychedelic molecule to treat cocaine addiction.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciSparc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
Details:
Based on statistically significant reductions in the reward effect as compared to cocaine, it was determined that MEAI, (5-methoxy-2-aminoindane, a novel psychoactive substance) is not rewarding.
Lead Product(s): 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
The patent application refers to the proprietary combination of Clearmind's MEAI (5-methoxy-2-aminoindan), a novel proprietary psychedelic treatment for addiction, with SciSparc's CannAmide™.
Lead Product(s): 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciSparc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 02, 2022
Details:
The Israeli-Canadian company holds several patents for the non-hallucinogenic compound MEAI (5-methoxy-2-aminoindane, a novel psychoactive substance). The company intends to seek additional patents for its compounds whenever warranted.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hebrew University of Jerusalem
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
CMND-100 (5-methoxy-2-aminoindane), is based on MEAI, a novel psychoactive compound, exerts a significant reduced desire to consume alcoholic beverages, and the company is developing it as a candidate therapy for the treatment of Alcohol Use Disorder("AUD").
Lead Product(s): 5-Methoxy-2-Aminoindane,CannAmide
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Earlier trials successfully showed a significant dose-dependent effect for MEAI treatment in reducing alcohol consumption in mice, with an additional significant effect achieved when combining CannAmide™ with a lower sub-effective MEAI dose.
Lead Product(s): 5-Methoxy-2-Aminoindane,CannAmide
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciSparc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
Two pre-clinical trials based on MEAI for CMND-100 ( 5-methoxy-2-aminoindane), exhibited a significant suppressive effect on alcohol consumption in mice.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciSparc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
The patent application followed a pre-clinical study that showed a significant dose-dependent effect for MEAI treatment in reducing alcohol consumption of treated animals, with additional significant effect for the CannAmide treatment at lower, sub-effective MEAI dose.
Lead Product(s): 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciSparc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 10, 2022
Details:
CMND-100, novel psychedelic-based therapeutic at doses of 40 mg/kg and higher, demonstrated significant suppressive effect on alcohol consumption, reducing the alcohol consumed significantly lower than untreated controls (p<0.01).
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciSparc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
The collaboration will include, examination of the benefit of integrating the core technologies of each company to explore the development of innovative psychedelic-centric drug candidates, with strong efficacy and safety profiles, targeting mental health-related diseases.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciSparc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 08, 2022
Details:
In accordance with the agreement, Aragen will do a process optimization and synthesis, manufacturing and supply of MEAI to Clearmind.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
